Introduction
Endometrial cancer is the most common gynaecologic malignancy. In recent years, a signi icant amount of new data gathered has facilitated a more accurate histologic classi ication consisting of two molecularly distinct subtypes. Type I, endometrioid histology, is the most common in numbers, correlates with oestrogen abundance and often has a favourable prognosis. Type II includes serous papillary or clear-cell tumours and is less frequent and shows more aggressive characteristics and low dependency on oestrogens.
Type I includes about 80% of all endometrial cancers and has been increasing in numbers in correlation with the use of oestrogen-only replacement therapies. Anovulation, nulliparity, early menarche and obesity have also been identi ied as risk factors. It is characterised by several molecular changes that make their appearances in the course of tumour progression. Most frequently seen alterations include microsatellite instability (MSI), phosphatase and tensin homolog gene (PTEN), K-Ras and β-catenin gene mutations 1 . MSI phenotype appears in 20% of Type I cases and includes inactivation of any of the proteins or genes that are included in the mismatch repair process: MLH1, MSH2, MSH3 and MSH6. In endometrial cancer, the most common event in the MSI mechanism is the inactivation of MLH1 caused by hypermethylation of the CpG islands that leads to epigenetic silencing of the gene promoter. Less frequently seen are the MSH6 mutations and MSH3 frame shift mutations. The presence of MSI may facilitate further molecular changes, through inactivation of genes with susceptible repeat elements like TGF-β1 receptors and IGFIIR, thus producing new tumour clones with enhanced invasive and metastatic potential. In addition, these tumours present a higher frequency of K-Ras mutations, which appear in about 30% of all Type I cases 2 . PTEN gene is located in 10q23 chromosome and its inactivation is most common in Type I tumours, appearing in more than 80% of cases that have developed tumours following a pre-malignant diagnosis 3 . Loss of heterozygosity due to mutations or deletions is common, as is the complete inactivation of both alleles. The main PTEN activity is expressed by a lipid phosphatase that converts inositol triphosphate to inositol biphosphate and therefore inhibits the signal transduction pathways regulated by the inositol triphosphate. Endometrial MSI tumours have more deletions, including at least three base pairs, and this group has very low incidence of mutations in the polyadenine repeat of exon 4 . The β-catenin gene is located in 3p21 and mutations are noted in 25% to 38% of Type I cancers 5 . In contrast to the previously described molecular alterations, the β-catenin mutations are usually found alone 6 . The β-catenin is part of the E-cadherin unit of proteins and plays a critical role in cell differentiation, maintenance of tissue architecture and Wnt signal transduction pathway.
Type II endometrial cancer is usually of serous papillary or clear-cell histology and is unrelated to oestrogen exposure and often arises in previously atrophic endometrium 7 most common molecular alterations observed are p53 and p16 mutations, Her-2 overexpression or ampli ication and loss of E-cadherin 8 . The p53 mutations appear in almost 90% of Type II cases. The mutated p53 produces a nonfunctional protein that acts as a double-negative inhibitor of the wild-type p53 and, as a result, DNAdamaged cells avoid apoptosis and survive further. Also, p53 mutations are identi ied in about 80% of endometrial intraepithelial carcinomas, which are considered to be the precursor lesions to the serous carcinoma development.
The p16 gene is located in 9p21 and encodes a cycle regulation protein. Inactivation by mutation results in uncontrolled cell proliferation and has been described in 45% of serous carcinomas and less often in clearcell ones.
Her-2/neu is an oncogene that belongs to the EGFR family and encodes a transmembrane receptor with tyrosine kinase activity and has a critical role in signal transduction pathways in many different tumours. Speci ic anti-HER2-targeted therapies have been in use for years in early and advanced breast cancer and, more recently, in advanced gastric adenocarcinoma. In serous endometrial adenocarcinomas, Her-2 overexpression has been reported in 45% of the cases and ampli ication in 70% of the cases 9 . E-cadherin is a transmembrane protein with ive extracellular domains and one intracellular domain that connects to the actin cytoskeleton. Reduction or loss of E-cadherin results in reduced cell-to-cell cohesion and increased cell motility. This event is more commonly seen in non-endometrioid tumours of low differentiation and poorer prognosis 2 . Following progress made in understanding several pathways of angiogenesis, cell proliferation and survival, signal transduction, genetic alterations and development of various targeted agents, endometrial cancer, among other solid tumours, has also been the ield of active research in recent years. Literature has already included a large number of basic and clinical research publications, but contribution to the routine clinical practice has been limited. Recurrent endometrial cancer remains an incurable disease, with limited treatment options, short progression-free intervals and poor overall survival for a signi icant number of patients. However, the concept of targeted treatments remains active and there are various agents that are currently under investigation in endometrial cancer, assessed in relation to the following: angiogenesis, cell cycle progression, hormone receptor activity, signal transduction and cell survival. This review will focus on the most recently published data, including experimental agents showing activity in endometrial cancer.
Discussion

Bevacizumab
Bevacizumab is the most widely studied antiangiogenic monoclonal antibody and is currently part of the standard treatment for advanced ovarian cancer, following two large Phase III randomised trials 9, 10 . In a Phase II trial in recurrent endometrial cancer 11 , 56 patients were treated with bevacizumab 15 mg/kg until disease progression or unacceptable toxicity. The majority of patients had received at least one line of chemotherapy and half of them had radiotherapy. Median PFS and overall survival times were 4.2 and 10.5 months, respectively. Twentyone patients were progression-free in 6 months. There was no clear association between response and particular histologic subtypes. The role of VEGF-A expression was investigated, concluding that high pre-treatment levels of circulating VEGF-A were correlated with poor outcome.
More recently in a Phase II setting, bevacizumab was combined with temsirolimus in recurrent endometrial cancer. A total of 53 patients received bevacizumab 10 mg/kg every 2 weeks and temsirolimus 25 mg IV weekly until the stage of disease progression or unacceptable toxicity 12 . More than 80% of patients had received one line of chemotherapy. There were 12 clinical responses and 23 patients remained progression-free for 6 months. Complications were as expected, including two intestinal-vaginal istulas, two GI perforations and a Grade 4 thromboembolism. Three deaths were potentially treatment related. Therefore, the combination seems active, but future studies will need to focus on safety issues.
The same combination of bevacizumab and temsirolimus has been investigated in combination with liposomal doxorubicin in a Phase I study 13 . Among the 15 endometrial cancer patients who participated, there were 6 responses. Maximum tolerated doses were 30 mg/m 2 for doxorubicin and 15 mg/kg every 21 days for bevacizumab.
Ombrabulin, a vascular-disrupting agent derived from combretastatin A4-phosphate is another agent under investigation in combination with bevacizumab. It induces rapid tumour vascular shutdown via endothelial cell damage and resistance may occur by surges in circulating endothelial progenitors (CEP) that repopulate the tumour vasculature. Experimental models suggest prolonged and synergistic anti-tumour activity when ombrabulin is combined with VEGFblockade, with reduction in CEP surge. A Phase I study evaluated the combination with bevacizumab in 39 heavily pre-treated patients. Ombrabulin was given in doses up to 50 mg/m 2 IV and bevacizumab up to 15 mg/kg every 21 days. There were no dose-limiting toxicities reported. Drug-related Grade 3 to 4 treatment adverse events were hypertension (6/39, 15%), intestinal perforation (2/39, 5%), headache (1/39, 3%), and pulmonary embolism (1/39, 3%). There were two partial responses in ovarian cancer patients and another two CA125 responses in endometrial cancers, lasting more than 6 months 14 . Further evaluation of the drug is anticipated.
Lenvatinib (E7080)
Lenvatinib is an oral receptor tyrosine kinase inhibitor targeting VEGFR1-3, FGFR1-4, RET, KIT and PDGFRβ. In May 2013 it was granted orphan drug designation (ODD) for the treatment of radioiodine-refractory differentiated thyroid cancer (RRDTC) by the European Commission. Currently, there is an ongoing randomised Phase III study versus sorafenib in hepatocellular carcinoma and there are Phase II trials in melanoma and lung cancer. Also, there is an active Phase I/II study in advanced renal cell cancer in combination with everolimus (NCT01136733).
In endometrial cancer, the irst results of a Phase II study have showed some activity and acceptable toxicity pro ile. The drug was given in 133 pre-treated patients with recurrent tumours at a standard dose of 24 mg PO once daily. Response rate as observed by the Independent Review Committee was 14.3%, median PFS was 5.4 months and median OS 10.6 months. Low baseline plasma level of Ang-2 (cut-off value <2082 pg/ml) was the only marker found to have a positive correlation with higher response rates, PFS and overall survival 15 .
Dovitinib (TKI258)
Dovitnib (DOV) is a potent receptor tyrosine kinase inhibitor of vascular endothelial growth factor receptor, platelet-derived growth factor receptor and FGFR. It is being studied as second-line treatment in advanced or metastatic endometrial cancer. Patient selection includes both mutated and wild-type ibroblast growth factor receptor-2 (FGFR2) 16 .
Cridanimod
Cridanimod is a novel small molecule that has been shown to increase progesterone receptor (PR) expression in rat endometrium. In a recently presented study it has been shown that combined progestin and cridanimod therapy can signi icantly improve survival of mice with highgrade, advanced endometrial cancer. Cridanimod signi icantly increased PR expression, and the concept of concurrent treatment with progestins is being considered as a way to upregulate hormone receptors and achieve higher response rates in endometrial cancer. This effect is potentially mediated by cridanimod-induced IFN-a and β expression 17 . Based on these activity data, further investigation seems appropriate to assess the agent in a more advanced level.
IMGN853
IMGN853 is an antibody-drug conjugate (ADC) comprising a folate receptor 1 (FOLR1)-binding antibody and the potent maytansinoid DM4. Endometrial cancer, among other solid tumours, frequently presents with FOLR1 overexpression and has been included in a Phase I study to test IMGN853 activity. The drug was given intravenously every 21 days with a dose escalation design. There was no signi icant toxicity observed, and there might be some activity in endometrial and ovarian cancer to be further investigated. The study is ongoing 18 .
Linsitinib
Linsitinib (OSI-906) is an oral dual inhibitor of insulin-like growth factor receptor-1 (IGF-1R) and insulin receptor (IR). Increased activity of IGF-1R and IR has been observed in solid tumours and is correlated with resistance to chemotherapy. 
BYL-719
BYL719 is an oral small-molecule inhibitor of the p110α catalytic subunit of phosphatidylinositol 3-kinase (PI3K), which is encoded by the PIK3CA gene. It inhibits proliferation of PI3Kα-driven cancer cell lines in vitro and causes regression of PIK3CA-mutant tumour models in vivo. It has been tested in a Phase I study 21 in 36 heavily pre-treated patients carrying a somatic mutation of PIK3CA, and among the seven responders, one had endometrial cancer. Dose-limiting toxicities were hyperglycaemia, nausea, vomiting and diarrhoea, and the maximum tolerated dose was 400 mg/d.
Conclusion
The need for more effective treatments in recurrent endometrial cancer offers signi icant motivation for testing new agents in therapeutic procedures. Identi ication of speci ic gene mutations or target molecules remains the focus for the ongoing research. There are promising data arising from the combination of approved drugs like bevacizumab with novel agents that are under investigation, and currently angiogenesis seems to be one of the more active areas of research in gynaecologic oncology in general and more speci ically in endometrial cancer. Also, the study of speci ic signal transduction pathways like the PI3K pathway may open up new possibilities for targeted treatment, as more targets are identi ied and tested, both as single agents and in combinations and/or with chemotherapy.
A great challenge to be tackled in the future is the need to identify subgroups of patients sharing molecular characteristics that can make them eligible for a speci ic agent, so that only potential re sponders receive each drug, keeping in mind that the highest goal in development of new therapies is individualisation of treatment.
